secwatch.observer — SEC 8-K summary
======================================

Issuer:     ESTABLISHMENT LABS HOLDINGS INC. (ESTA)
CIK:        0001688757
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001688757-24-000056
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Establishment Labs reports Q1 revenue down 20% YoY; narrows operating loss sequentially; reaffirms 2024 guidance
--------------------------------------------------------------------------------

- Q1 2024 revenue $37.2M (down 20% YoY from $46.5M); net loss $16.2M vs $11.9M loss in Q1 2023.
- Adjusted EBITDA loss improved to $3.7M from $17.3M in Q4 2023; operating loss $8.8M vs $22.1M in Q4 2023.
- Cash balance $73.0M, up $32.9M from Dec 31, 2023 due to private placement; 2024 revenue guidance reaffirmed at $174M-$184M.
- Company presented 4-year Motiva US IDE study data with low capsular contracture/rupture rates; expects FDA approval in 2024.
- Launched Motiva implants in China and Flora tissue expander in US; cost reduction initiatives lowered SG&A and R&D expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1688757/000168875724000056/0001688757-24-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1688757/000168875724000056/esta-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001688757-24-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer